Combination of Candidate Microbicides Cellulose Acetate 1,2-Benzenedicarboxylate and UC781 Has Synergistic and Complementary Effects against Human Immunodeficiency Virus Type 1 Infection

Shuwen Liu, Hong Lu, A. Robert Neurath, and Shibo Jiang*

Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York

Received 10 August 2004/Returned for modification 8 November 2004/Accepted 31 December 2004

By the end of 2003, more than 60 million people worldwide had been infected by the human immunodeficiency virus (HIV), and over one-third of them died of AIDS (40). Due to the unavailability of anti-HIV vaccines, development of topically applied microbicides is urgently needed since sexual transmission is the major cause of HIV infection (9, 19, 36, 37, 39).

There are three major categories of candidate microbicides with different mechanisms of action: (i) inactivating HIV-1 and other sexually transmitted disease (STD) pathogens, including surfactants (e.g., nonoxynol-9 [21] and C31G [3]) and acidifying agents (e.g., BufferGel [23]); (ii) blocking HIV-1 attachment/fusion/entry, such as long-chain anionic polymers (e.g., Carraguard [9] and PRO 2000 [24]) and fusion inhibitors (e.g., T20 [25]); and (iii) disrupting intracellular HIV replication, such as reverse transcriptase inhibitors (RTIs) (38). Recently, in the first completed microbicide phase II/III clinical trial, nonoxynol-9 failed to protect against HIV-1 infection, presumably due to inflammatory lesions associated with frequent nonoxynol-9 use (41). Therefore, more effective microbicides or microbicide combinations are needed urgently. Cellulose acetate 1,2-benzenedicarboxylate (CAP), a mixture of polymers with a mean molecular mass of 45 to 60 kDa, is a pharmaceutically inert microbicide and has low cytotoxicity and no immunoinflammatory side effects as determined in a human in vitro model of vaginal inflammation (11, 13). This suggests that CAP is an ideal candidate microbicide for preventing sexual transmission of HIV-1 and other STD pathogens (22, 29).

In order to develop more effective anti-HIV-1 microbicides, we intend to design combinations of CAP with other candidate microbicides that have mechanisms of action different from the mechanism of CAP and that may be synergistic with CAP in inhibiting HIV-1 infection. We are especially interested in candidate microbicides in the third category described above, i.e., RTIs. Currently, two nonnucleoside RTIs (NNRTIs), UC781 (Biosyn, Huntingdon Valley, PA) (6, 45) and TMC120 (Tibotec-Virco, Mechelen, Belgium) (12, 42), and one nucleotide RTI (NRTI), tenofovir (Gilead, Foster City, CA), have been shown to block the coreceptor (CXCR4 or CCR5) binding sites on gp120, and eliciting “dead-end” gp41 six-helix bundle formation on the virus envelope (28, 30). It can also block the infection in rhesus macaque and pig-tailed macaque monkeys (4, 33). In addition, CAP also has microbicidal activity against a broad spectrum of STD pathogens, including herpesviruses HSV-1, HSV-2, cytomegalovirus, Neisseria gonorrhoeae, Trichomonas vaginalis, Haemophilus ducreyi, Chlamydia trachomatis, Treponema pallidum, and bacteria associated with bacterial vaginosis (31). CAP has low cytotoxicity and no immunoinflammatory side effects as determined in a human in vitro model of vaginal inflammation (11, 13). This suggests that CAP is an ideal candidate microbicide for preventing sexual transmission of HIV-1 and other STD pathogens (22, 29).

The phase I clinical trial of CAP is ongoing in multicenters (35).

The combination of two candidate microbicides, cellulose acetate 1,2-benzenedicarboxylate (CAP), a polymer that blocks human immunodeficiency virus type 1 (HIV-1) entry by targeting gp120 and gp41, and UC781, a tight-binding HIV-1 reverse transcriptase inhibitor (RTI), resulted in effective synergy for inhibition of MT-2 cell infection by HIV-1IIIB, a laboratory-adapted virus strain. The 95% effective concentration values for the combination were reduced about 15- to 20-fold compared with those corresponding to the single compounds. The combination of CAP and UC781 is also synergistic in inhibiting infection of peripheral blood mononuclear cells by a primary HIV-1 isolate, 92US657. Combinations of CAP with other RTIs, such as efavirenz or zidovudine, also had significant synergistic effects on the inhibition of HIV-1 infection. In addition, CAP and UC781 had complementary effects against HIV-1 infection since (i) CAP inhibited infection by the UC781-resistant strain HIV-1IIIB A17 and (ii) pretreatment of MT-2 cells with UC781, but not CAP, abolished subsequent infection after removal of the compound. This suggests that the combination of CAP and UC781 represents a promising candidate microbicide for prevention of sexual transmission of HIV-1.
**MATERIALS AND METHODS**

**Reagents.** MT-2 cells, HIV-1<sub>IIIB</sub>, HIV-1<sub>IIIB</sub> A17, anti-p24 monoclonal antibody (183-12H-5C), zidovudine (AZT), and efavirenz were obtained from the National Institutes of Health AIDS Research and Reference Reagent Program, contributed by D. Richman, R. Gallo, E. Emini, B. Chesebro, and H. Chen, respectively. CAP was a gift from Eastman Chemical Company (Kingsport, TN). A soluble form of CAP was prepared every 6 weeks as a 30 mg/ml stock solution in 30 mM sodium acetate buffer (pH = 5.8). Working solutions of CAP and acetate buffer control were prepared fresh for each experiment in appropriate cell culture medium. The stability of CAP in stock solution and culture medium was confirmed by the ruthenium red method (26). UC781 was kindly provided by D. Ho at the Aaron Diamond AIDS Research Center, The Rockefeller University (New York, NY).

Detection of HIV-1 replication as measured by p24 antigen production. The inhibitory activity of compounds on HIV-1 infection was determined as previously described (28, 44). In brief, 10<sup>5</sup> MT-2 cells were infected with HIV-1<sub>IIIB</sub> or HIV-1<sub>IIIB</sub> A17 (100 times the 50% tissue culture infective dose [TCID<sub>50</sub>]) in 200 µl of RPMI 1640 medium containing 10% fetal bovine serum (FBS). Media were changed three times with 300 µl of RPMI 1640 medium to remove unbound compounds, and then every 3 days. The supernatants were collected 7 days postinfection and p24 production and EC<sub>50</sub> values were calculated as described above. The percent inhibition of p24 production was calculated as previously described (28).

Figure 1. Synergistic effect of CAP in combinations with UC781 (A), efavirenz (B), and AZT (C) against HIV-1<sub>IIIB</sub> infection of MT-2 cells. The effective concentrations for inhibition of HIV-1 replication by a compound alone and in combination with another compound are plotted in two curves. The length of a line with two arrows between two curves represents the dose reduction (n-fold) of a compound when it was tested alone and in combination with another compound. Data are the means of three independent assays performed in triplicate.

**Assessment of in vitro cytotoxicity.** The in vitro cytotoxicity of compounds on MT-2 cells was measured by the XTT [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-5-(phenylamino) carbonyl-2H-tetrazolium hydroxide] assay (27). Briefly, 100 µl of a compound at graded concentrations was added to equal volumes of cells (5 x 10<sup>5</sup> cells/ml) in wells of 96-well plates. After incubation at 37°C for 4 days, 50 µl of XTT solution (1 mg/ml) containing 0.02 µM of phenazine methosulphate was added. After 4 h, the absorbance at 450 nm was recorded in an ELISA reader (Ultra 386; TECAN, Research Triangle Park, NC). Recombinant protein p24 purchased from US Biological (Swampscott, MA) was included for establishing standard dose-response curves. Each sample was tested in triplicate. The percentage of inhibition of p24 production was calculated as previously described (28). The effective concentrations for 50, 70, 90 and 95% inhibition (EC<sub>50</sub>, EC<sub>70</sub>, EC<sub>90</sub>, and EC<sub>95</sub>, respectively) were calculated using a computer program, designated CalcuSyn (8), kindly provided by T. C. Chou (Sloan-Kettering Cancer Center, New York, N.Y.).

Assessment of in vitro cytotoxicity. The in vitro cytotoxicity of compounds on infection of peripheral blood mononuclear cells (PBMC) by a primary HIV-1 isolate was determined as previously described (17). Briefly, PBMC were isolated from the blood of healthy donors at the New York Blood Center by standard density gradient centrifugation using Histopaque-1077 (Sigma). The cells were cultured in 75-cm<sup>2</sup> plastic flasks at 37°C for 2 h. The nonadherent cells were collected and resuspended at 5 x 10<sup>6</sup> cells in 10 ml of RPMI 1640 medium containing 10% FBS, 5 µg/ml phytohemagglutinin and 100 U/ml interleukin-2 (IL-2; Sigma), followed by incubation at 37°C for 3 days. The phytohemagglutinin-stimulated cells were infected with a primary HIV-1 isolate 92US657 (clade B) at a 0.01 multiplicity of infection in the presence or absence of compounds. Culture media were changed on the second day and then every 3 days. The supernatants were collected 7 days postinfection and tested for p24 antigen by ELISA as described above. The percent inhibition of p24 production and EC<sub>50</sub> values were calculated as described above.
were transferred to wells of culture plates and infected with HIV-1 IIIB (100 TCID₅₀)
washout experiment. In brief, MT-2 cells (10⁵ cells/ml) in RPMI 1640 medium
Franklin Lakes, NJ) with a low binding property were used for repeating the
plates, Falcon 5-ml polystyrene round-bottom tubes (Becton Dickinson Labware,
to the nonspecific binding of the compound to surface of wells of the culture
mixed with equal volumes of 5% Triton X-100, and assayed for p24 antigen using
day postinfection, 100
and fresh medium containing no testing compounds was added. On the fourth
containing 10% FBS at 37°C overnight. The culture supernatants were removed
polystyrene tubes at 37°C for 1 h, followed by three washes with 4 ml of RPMI

To exclude the possibility that the “memory” effect of UC781 (2, 5, 20) is due
to the nonspecific binding of the compound to surface of wells of the culture
plates, Falcon 5-ml polystyrene round-bottom tubes (Becton Dickinson Labware,
Franklin Lakes, NJ) with a low binding property were used for repeating the
washout experiment. In brief, MT-2 cells (10⁵ cells/ml) in RPMI 1640 medium
containing 10% FBS were incubated with UC781 at graded concentrations in
polystyrene tubes at 37°C for 1 h, followed by three washes with 4 ml of RPMI
1640 medium or no wash (for the controls). Then, the MT-2 cells (10⁵ cells/well)
were transferred to wells of culture plates and infected with HIV-1Ⅰ（100
TCID₅₀). Virus replication in MT-2 cells was determined by measuring p24
production as described above.

Synergy analysis. Inhibition data from three independent assays were aver-
ageed and analyzed for cooperative effects by using the CalcuSyn program for
calculating the combination index (CI) as described (8). In all analyses, CAP and
the RTIs were assumed to act noncompetitively, which leads to a more conser-
vative estimate of synergy. CI values of <1 and >1 indicate synergy and antag-
onism, respectively. Dose reductions were calculated as the compound concen-
trations required for inhibition of HIV-1 replication when the compound was
used alone and in combination (8). Statistical analysis was performed by a
one-way analysis of variance method using Origin version 6.1 software (Origin-
Lab Corp., Northampton, MA).

### RESULTS

Combination of CAP with UC781 is synergistic against HIV-1 infection. The ratio of compounds in a combination (about 1:1) was determined based on their respective EC₅₀
values. The synergistic effect can be calculated as long as the
compounds in the combination are mixed at concentrations
having equal or similar potencies. In preliminary studies, the
average EC₅₀ ratio for CAP and UC781 for inhibiting the
laboratory-adapted and primary HIV-1 strains was about
2,000:1 (wt/wt; ranging from 1,258:1 to 3,860:1). Based on the
molar concentrations, the EC₅₀ ratio for CAP and UC781 is
about 10:1 to 18:1 since the molecular mass of CAP (about
345 to 60 kDa) is much larger than that of UC781 (335.9 Da). We prefer
to use the weight concentrations, rather than the molar concen-
trations, since CAP is a mixture of polymers with different
molecular sizes. Therefore, the combination of CAP and UC781
at a weight ratio of 2,000:1 was tested for possible synergistic
effects on the inhibition of HIV-1ⅠⅠⅠⅠⅠ infection as measured by
ELISA for p24 antigen. The results are shown in Fig. 1A
and Table 1. When CAP and UC781 were used in combination,
their EC₅₀, EC₇₀, EC₉₀, and EC₉₅ values for inhibition of HIV-
1 replication decreased significantly. Approximately 15-fold
less CAP and 20-fold less UC781 were needed to inhibit HIV-1

### Table 1. Combination index and dose reduction values for inhibition of HIV-1 infection on MT-2 cells by combinations of CAP with HIV-1 RTIs

<table>
<thead>
<tr>
<th>% Inhibition</th>
<th>CAP</th>
<th></th>
<th>RTI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CI</td>
<td>Conc (µg/ml)</td>
<td>Dose reduction</td>
</tr>
<tr>
<td></td>
<td>Alone</td>
<td>Mix</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>0.2364</td>
<td>15.176</td>
<td>2.685</td>
</tr>
<tr>
<td>70</td>
<td>0.1904</td>
<td>27.310</td>
<td>3.640</td>
</tr>
<tr>
<td>90</td>
<td>0.1392</td>
<td>69.646</td>
<td>9.510</td>
</tr>
<tr>
<td>95</td>
<td>0.1192</td>
<td>116.933</td>
<td>7.729</td>
</tr>
</tbody>
</table>

### Table 2. Combination index and dose reduction values for inhibition of infection by a primary HIV-1 isolate 92US657 of PBMC

<table>
<thead>
<tr>
<th>% Inhibition</th>
<th>CAP</th>
<th></th>
<th>UC781</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CI</td>
<td>Conc (µg/ml)</td>
<td>Dose reduction</td>
</tr>
<tr>
<td></td>
<td>Alone</td>
<td>Mix</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>0.3878</td>
<td>29.823</td>
<td>5.480</td>
</tr>
<tr>
<td>70</td>
<td>0.4161</td>
<td>45.119</td>
<td>7.565</td>
</tr>
<tr>
<td>90</td>
<td>0.4761</td>
<td>87.260</td>
<td>12.648</td>
</tr>
<tr>
<td>95</td>
<td>0.5182</td>
<td>125.712</td>
<td>16.809</td>
</tr>
</tbody>
</table>

* a Combinations of CAP with UC781 (2,000:1 [wt/wt]) were used. Data are the means of triplicate experiments.
infection by 95% compared with the respective compounds used alone. The CI values ranged from 0.12 to 0.24, suggesting that the combination of the candidate microbicides CAP and UC781 is potently synergistic in inhibiting HIV-1 infection. The CI values for 50 to 95% inhibition by combinations of CAP and UC781 ranged between 0.38 and 0.52, suggesting potent synergy for CAP and UC781 at a weight ratio of 2,000:1 (Table 2).

The combination of CAP and UC781 did not show synergistic effects on cytotoxicity (CI, 1.02). The CC50 of CAP was 2.34 ± 0.052 and 2.480 ± 0.076 mg/ml (P > 0.05) when tested alone and in combination with UC781, respectively. This suggests that the cytotoxicity of CAP does not increase when it is used in combination with UC781. UC781 has a selectivity index (selectivity index = CC50/EC50) of about 23,550 (CC50, 94.4 ± 13.2 µg/ml; EC50, 0.004 ± 0.001 µg/ml), indicating that UC781 has very low cytotoxicity compared to its highly potent anti-HIV-1 activity.

Combination of CAP with other RTIs also has synergistic effect on inhibition of HIV-1 infection. To determine whether combinations of CAP with other RTIs with lower reverse transcriptase (RT)-binding affinity also result in synergistic anti-HIV-1 activity, we selected efavirenz, another NNRTI, and AZT, an NRTI, for parallel testing since both drugs are widely used for treatment of HIV-1 infection. As shown in Fig. 1B and C and Table 1, combinations of CAP with either efavirenz or AZT showed potent synergistic effects in inhibiting HIV-1 infection, with CI values ranging from 0.14 to 0.33 and about 3- to 21-fold dose reductions. These results indicate that CAP may be combined with not only UC781 but also other RTIs to design combination microbicides for prevention of mucosal HIV-1 transmission.

**TABLE 3. Inhibitory activity of CAP and RTIs on infection by HIV-1 IIIB and its variant strain A17 that is resistant to NNRTIs**

<table>
<thead>
<tr>
<th>Agent</th>
<th>EC50 (µg/ml) for inhibition of p24 production</th>
<th>Dose increase (n-fold)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HIV-1IIIB</td>
<td>HIV-1IIIB A17</td>
<td></td>
</tr>
<tr>
<td>CAP</td>
<td>19.01000 ± 4.08</td>
<td>20.17000 ± 4.46</td>
<td>1.1 ± 0.1</td>
</tr>
<tr>
<td>UC781</td>
<td>0.00405 ± 0.00112</td>
<td>&gt;4.0</td>
<td>&gt;1036.3 ± 266.3</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>0.00051 ± 0.00004</td>
<td>0.02686 ± 0.01004</td>
<td>52.2 ± 16.8</td>
</tr>
<tr>
<td>AZT</td>
<td>0.04202 ± 0.00520</td>
<td>0.03309 ± 0.00370</td>
<td>0.8 ± 0.1</td>
</tr>
</tbody>
</table>

* Data are the means of two independent assays performed in triplicate.
can render these cells refractory to subsequent HIV infection in the absence of exogenous drug (5). Recently, Kiselyeva et al. confirmed this point by briefly treating ex vivo human lymphoid tissue with UC781 (20). This so-called memory effect would make UC781 an ideal candidate microbicide. In this study, MT-2 cells were pretreated with UC781 or CAP for 1 h, and then the unbound compounds were removed by washing the cells three times. In the controls, the cells were not washed, with the result that the unbound compounds were retained. HIV-1 replication in the cells with and without washes was compared. Without washes, CAP effectively inhibited HIV-1 infection of MT-2 cells. However, after washes to remove unbound CAP, the cells were not protected from HIV-1 infection (Fig. 3A). In contrast, pretreatment of MT-2 cells with UC781 and removal of the unbound compound by washes reduced subsequent HIV-1 infection (Fig. 3B). The cells pretreated by the UC781 and CAP combination were also resistant to HIV-1 infection (Fig. 3B).

One may argue that the so-called memory effect of UC781 may be due to its nonspecific binding to the surface of wells of culture plates (39, 42). To exclude this possibility, we repeated the washout experiment using polystyrene tubes that have low binding properties. MT-2 cells were pretreated with UC781 in the polystyrene tubes. After extensive washing, the pretreated cells were transferred to wells of culture plates and infected with HIV-1. HIV-1 replication in MT-2 cells pretreated by UC781 was determined by measuring p24 production. As shown in Fig. 3C, there was no significant difference in HIV-1 replication in UC781-pretreated cells with or without washes (P = 0.7091). This suggests that the memory effect of UC781 is not due to its nonspecific binding to the surfaces of wells of culture plates.

**DISCUSSION**

Clinical applications of antiretroviral drugs with different targets in combinations (i.e., cocktail regimens) have shown significant synergism in inhibiting HIV-1 infection, reducing adverse effects, and delaying the emergence of drug resistance (16). It is expected that combinations of topical microbicides with distinct mechanisms of action may also have synergistic effects on the prevention of sexual transmission of HIV-1 (36).

Although CAP has potent anti-HIV-1 activity and broad-spectrum microbicidal activity against other STD pathogens (31), it may be more effective for preventing sexual transmission of HIV-1 if it is combined with other candidate microbicides with mechanisms of action different from the mechanism of CAP. We previously demonstrated that there is synergy between CAP and soluble CD4 for inhibiting HIV-1 infection since these two molecules bind to the different regions on gp120 (28). Soluble CD4 is not an ideal anti-HIV-1 microbicide since it has only moderate antiviral activity against primary HIV-1 strains and is too expensive to be used topically. Therefore, it is necessary to search for other candidate microbicides suitable for combination with CAP.

In the present study, we demonstrated that the combination of CAP with another candidate microbicide, UC781, a tight-binding NNRTI, results in significant synergy for inhibiting infection by both laboratory-adapted and primary HIV-1 strains. Other RTIs with lower RT-binding affinity than UC781,
such as efavirenz and AZT, when combined with CAP also had synergistic anti-HIV-1 activity. The RTIs could not have enhanced CAP-mediated inhibition on HIV-1 entry since there was no synergy when a combination of CAP and UC781 was tested in a cell-cell fusion assay (data not shown). We believe that the synergistic effect of the CAP/UC781 combination is due to the fact that CAP is targeted to earlier stages of the HIV-1 replication cycle, virus fusion and entry, while UC781 acts on later stages of virus infection, reverse transcription. Therefore, a combination of CAP with UC781 for prevention of sexual transmission of HIV-1 may have the following advantages: (i) maximization of anti-HIV-1 activity because of synergistic effects, (ii) minimization of potential toxic effects due to dose reduction, and (iii) complementary or cooperative microbical activity.

Although CAP used alone is a virucidal agent and/or blocks HIV-1 entry, some residual virus particles might escape from CAP-mediated antiviral activity and enter into cells. If UC781 is present, it will work as a secondary inhibitor against residual virus. Especially if these residual virions pass through the multilayered epithelium and enter into draining lymph nodes, where the large-molecule CAP is unlikely to reach, the small-molecule compound UC781 may enter these locations and block infection by these virions. In addition, UC781 pretreatment of cells renders them refractory to HIV-1 infection (6, 20), while CAP does not have such properties. UC781 is potent in inhibiting in vitro HIV-1 infection (1). However, it may not be efficient in vivo against some primary HIV-1 isolates with preexisting resistance to NNRTIs. For example, HIV-1 group O strains are de novo resistant to current NNRTIs (15, 32), suggesting that CAP can be used for preventing sexual transmission of NNRTI-resistant variants. Furthermore, UC781 has no documented activity against other STD pathogens. This shortcoming can be overcome by combining UC781 with CAP, since CAP has potent microbicidal activity against a broad spectrum of STD pathogens. In summary, the combination of CAP and UC781 resulted in significant synergistic and complementary effects against HIV-1 infection. This was translated into meaningful dose reductions for each compound. These findings provide a strong rationale for developing combinations of microbicides with distinct mechanisms of action for the prevention of sexual transmission of HIV-1 and other STD pathogens.

ACKNOWLEDGMENTS

We thank David Ho at Aaron Diamond AIDS Research Center, The Rockefeller University, for providing UC781 and Nathan Strick for preparing CAP solutions. This work was supported by grants from the National Institutes of Health (HD41761 and HD48957).

REFERENCES


